Register
Login:
Share:
Email Facebook Twitter


Exclusive: Hardman & Co call the lithium market: is a change in trend happening?
Tower Resources identify 18 million barrels of contingent reserves worth $118M in Cameroon


Scancell Holdings Share Chat (SCLP)



Share Price: 7.80Bid: 7.60Ask: 8.00Change: 0.00 (0.00%)No Movement on Scancell Hldgs
Spread: 0.40Spread as %: 5.26%Open: 7.80High: 7.80Low: 7.80Yesterday’s Close: 7.80


Share Discussion for Scancell Holdings


Thread View

Please login or register to post a message on Share Chat.

Posts per page:

TorquayFan
Posts: 5,303
Opinion:Strong Buy
Price:7.80
Good Morning All
Today 04:53
Ivy - 'inclusive' indeed.

RW 13.55 Friday - a helpful tweet from Trinity Delta of that article in 'Nature'. How nice to see an 'International Journal of Science' current edition and a mention of Scancell ! More please . .
https://www.nature.com/articles/d41586-018-07645-x?

WF 14.05 Friday - thanks for that link. Will watch later. (BTW TUFC top the table).

MattR - 21.07 Friday - £2 would be a good start.

Me - a quiet week and SP langours still. Something special next week ? GLA
 
Ivyspivey
Posts: 8,818
Opinion:No Opinion
Price:7.80
Great posts tonight
Fri 23:51
Imo this is what a BB should be about honest expression of views but also being tolerant of the fact that every one’s circumstances/attitude to risk/knowledge and understanding of a particular share and of investing on AIM is different.
That is why people often disagree as their agenda,experience,knowledge,trust,length of investment perspective,ability to make sound decisions is very individual.
Listen to no one and make your own decisions based on your own research and try not to think of the SP as being reflective of true value but at the same time accepting that the SP does reflect value at any particular point in time.
But hopefully tonight does reflect a much more includpdive board
,
RuckRover
Posts: 1,457
Opinion:No Opinion
Price:7.80
RE: matt and ruck
Fri 22:57
Ray,
No apology necessary, I don’t feel insulted. It was Matt that said that not me, although I fully get where Matt is coming from - thanks for the support Matt.
I do accept that you have held as long (slightly longer actually) than me so no accusation of being a “Johnny come lately “ from me. It is somewhat puzzling why you have not been vocal or chosen not to fully understand the science until relatively lately. We did discuss this a while back, so no need to reopen the debate as far as I’m concerned.

The only thing I would say to you is please don’t fall into the Inan trap of trying to dictate to people whether they should buy, hold or sell. It is a completely personal decision how much money, what proportion of portfolio to throw at this and equally how risky someone considers it.
RayPointer
Posts: 529
Opinion:No Opinion
Price:7.80
matt and ruck
Fri 21:29
You are misquoting me
I said "you should consider selling".
I too am a long term holder since March 2012.
I totally understand your frustration and I feel it too. We could have closed a deal on the strength of the SCIB1 trial results but my assessment is that big pharma were biased against cancer vaccines at that time.
About 12 months ago I too was getting nervous about my investment so at that point I decided to learn more about the science and the more I learnt the more my investment made sense.
However, apologies to you Ruck if you feel I insulted you.
ATB
MattRempit
Posts: 96
Opinion:Strong Buy
Price:7.80
RE: On a different note
Fri 21:07
Bit unfair on Ruck.
I totally agree that no matter how good the science is the SP will slide unless you have good people on the Board.
I'm a very long term holder here and I'm nervous that the Board aren't doing anything for us.
I don't want to always appear to be negative on here but it's getting ridiculous now.
No matter how many brilliant posts we have have commending the science, we will leave here empty handed and out of pocket unless there is a great person or team of people making a deal.
That's the brutal truth.
I'm scunnered and sickened after the last fundraising. This is now very serious. I have stated in the past that I think a fair price for all intellectual property is 2 pounds. They real price if everything comes to fruition is probably closer to 10 but adding in the corrupt AIM factor I always believed 2 pounds for private investors.
I fear we are being played and no matter how many insightful posts and links, we will be at the mercy of sharks soon.
And for the record, to come away with a statement saying 'perhaps you should sell' is insulting to long term holders.
Many of us are well under water and have NEVER been rewarded for holding long term.
So telling someone to sell is rather insulting. Especially since we have probably held way longer than yourself.
ratcliffewriter
Posts: 8,201
Opinion:Strong Buy
Price:7.80
RE: swamp
Fri 21:06
Pig implants? They did that to the White House at the last election. A Tamworth ginger lookalike, but less intelligent.
RuckRover
Posts: 1,457
Opinion:No Opinion
Price:7.80
RE: RR
Fri 19:50
Wild, I agree, I’ve never had a problem with the results to date.
RuckRover
Posts: 1,457
Opinion:No Opinion
Price:7.80
RE: On a different note
Fri 19:44
Ray, where on earth did you imagine I’m not impressed with the Science? The data and result cannot fail to impress. Am I impressed? Yes. Does this guarantee commercial success? No. (IMO). It’s my money and I’ll hold if I want to. I’m prepared to write it all off rather than sell at these levels.
nomlungu
Posts: 2,134
Opinion:No Opinion
Price:7.80
swamp
Fri 19:36
another orangutan movement from the swamp

https://theconversation.com/trump-administration-ban-on-nih-use-of-fetal-tissue-should-worry-all-scientists-108660

this xxxx's up a number of my bio interests

and I thought that the us was ready for pig implants a while ago
Wildforce
Posts: 10,065
Opinion:Strong Buy
Price:7.80
T cell activation ..
Fri 18:17
In the talk by JPA .. all the research referred to is in mice with immune systems and how the different types of inhibition can affect different groups of t-cells .. however, there is nothing in that piece that mentions immune compromised patients .. patients that have depleted t-cell populations and without the ability to produce new populations ..

This is where car-t or tcr therapy comes into play .. I’m surprised this wasn’t mentioned in the presentation ..

Lindy Durrant and scancell really are looking to cover all bases in all cancers in my opinion !

Take care all .. just some thoughts as ever !
Wildforce
Posts: 10,065
Opinion:Strong Buy
Price:7.80
RR
Fri 18:01
Did you watch the James p Allison presentation !?

Specifically regarding late stage melanoma patients .. [he says] if a patient survives longer than four years then we can call them cured ... these lengths of survival in this patient population used to be unheard of ..

The market may not be very excited about Scancells achievements to date .. but I still am .. still building !

Take care ..
RayPointer
Posts: 529
Opinion:No Opinion
Price:7.80
RE: On a different note
Fri 17:55
Ruck
If you are not impressed with Scancell's science then you should consider selling.
It's too much of a gamble.
RuckRover
Posts: 1,457
Opinion:No Opinion
Price:7.80
RE: On a different note
Fri 17:35
> the 5 year results and the memory effect<
5 year result - Financially dire. Memory? Oh yes, I remember the SP in the 60s, 50s,40s,30s,20s, teens and single digit!

Posting the same snippet multiple times isn't going to change that.

Note: For those who are/were on the trial I am GENUINELY pleased for.
RayPointer
Posts: 529
Opinion:No Opinion
Price:7.80
RE: On a different note
Fri 15:52
Nice one Rats

"Scancell, a cancer-immunotherapy company in Oxford, UK, has used electroporation to transfer a gene encoding a lab-designed antibody that primes immune cells called T cells to target tumours in people with melanoma. In 2017, the company reported that the treatment safely induced an immune response against the cancer."

A bit of an understatement IMO looking at the 5 year results and the memory effect. Also, it looks like Lindy is moving on to an even better delivery system in the SCIB2 combo trial.
Wildforce
Posts: 10,065
Opinion:Strong Buy
Price:7.80
While its quiet ..
Fri 14:05
I just watched this .. Gets a bit heavy in the middle but his short summary at the end says it all ..

https://www.youtube.com/watch?v=0kuh7G9CP9Y&t=0

Take care all ..
inanaco
Posts: 28,188
Opinion:No Opinion
Price:7.80
RE: Yawn . . .
Fri 14:00
Scancell has £10m in the bank... "for me" is yet again a delusional statement ... why on earth would cancer research consider a proposal from a consortium that was financially unstable ?
why would ISA pharma sign a deal and commit to a partner that was financially unstable
why would BioNtech collaborate with a company that was financially unstable

its only one investor that is unstable weak and desperate ... as far i as i can see desperate to create an image of Risk
ratcliffewriter
Posts: 8,201
Opinion:Strong Buy
Price:7.80
On a different note
Fri 13:55
RuckRover
Posts: 1,457
Opinion:No Opinion
Price:7.80
RE: Yawn . . .
Fri 13:48
It's a shame you seem to be bored by your own posts!

Here is what I put: (Exactly as written)

Question is, how low can it go? For me, already past the point of selling. It either a recovery or a write off.

Note the words "FOR ME". Just being truthful. FOR ME (personally) it has dropped too low for me to sell. So FOR ME it is a case of waiting for a) it to recover (which I sincerely hope it will) or b) become worthless (which I sincerely hope it WON'T)

And before you start bleating about the latter not being possible, it IS. And, not necessarily because the medicine/treatment fails but for commercial/financial reasons. You really need to wake up to the possibilities (and, dare I say {quietly} RISKS!!!

ATB
TorquayFan
Posts: 5,303
Opinion:Strong Buy
Price:7.80
Yawn . . .
Fri 12:53
RR. Again ! OMG. 'Mai kao jai' most of your Wed 23.30 but I can comment on 'negative' and 'realistic'.

Negative (or positive) can be about - perception of the level of water in the bucket ? Geddit ?
And it's possible to be 'realistic' with optimism or 'realistic' with pessimism.

When I read your Wed 23.30 - you posted - ''For me, already past the point of selling. It either a recovery or a write off''. Ouch ! I thought you'd gone from - (yonks ago) - constructive poster - to cynic to - (nearly) - 'Tr*ll'.

Anyway, to spare the BB any more of this exchange - BFN Last to you FAW.

To cheer you up - is that possible ? Thursday 23.20 I posted some appreciation for a 'marketwatch'. (No space). It appeared on the BB with 4 x * amidst. I wondered why and asked Admin ?

BFN
RuckRover
Posts: 1,457
Opinion:No Opinion
Price:7.80
RE: Ruck Rover / Gazza
Fri 07:19
Morning TF,
While you are checking out the word “original” you may want to check:
The difference between “conclusion” and “question”
The difference between “negative” and “realistic”
TorquayFan
Posts: 5,303
Opinion:Strong Buy
Price:7.80
''Nature'' - 12th Dec 2018
Fri 01:44
In this article, ''The genetic shortcut to antibody drugs'' under a section ''It's all in the delivery'' - our dear 'ole Scancell actually gets a mention . . . . .

''Scancell, a cancer-immunotherapy company in Oxford, UK, has used electroporation to transfer a gene encoding a lab-designed antibody that primes immune cells called T cells to target tumours in people with melanoma. In 2017, the company reported that the treatment safely induced an immune response against the cancer.''

https://www.nature.com/articles/d41586-018-07645-x?

Nice link from Bermuda so thanks to him. GLA
TorquayFan
Posts: 5,303
Opinion:Strong Buy
Price:7.80
C7
Thu 23:20
Good to see you posting C7 - I enjoy the market watch and the optimism, from you and Crumbs etc.

And I'll join RR in wishing for this : ''News that the FDA issue has been resolved and trials WILL start as planned''. That would be a nice Christmas present . . .
TorquayFan
Posts: 5,303
Opinion:Strong Buy
Price:7.80
Ruck Rover / Gazza
Thu 23:10
The discussion about TriGrid V1 or V2 was constructive. Posters worked with each other and in the end, it was confirmed that as yet, a Study in the USA using V2 had not been found atm. Study 6 of the 14 in the link which commenced only a few weeks ago, Sep 17th, was using the V1, confirming WF and Inan position. Bermuda noted the comments of Dr Sally at the AGM 24 mins 25 secs which confirmed that Scancells IND includes the use of TriGrid2.

https://drive.google.com/file/d/12QRlLjAojWKukLipQ4_1MkpOZOUTjHoJ/view

(I was travelling yesterday - Chantaburi - Chiang Mai - a long drive. Just noticed your Wed 11.30 pm. I wondered what the point of your post was as I had conceded ambiguity before ? Then I saw your negative conclusion with which I don't agree although I am similarly impatient for a better SP. IMO there's lots of reasons for Scancell holders to be optimistic and I'm not alone in that).

ATB
CHELSEA7
Posts: 33,718
Opinion:No Opinion
Price:7.80
Volume 358k
Thu 20:06
Buys 358k

Sells 000000

A welcome sight!! Night you guys.
crumbs
Posts: 12,609
Opinion:No Opinion
Price:7.80
How to
Thu 18:28
Turn your Biotech startup into a successful company:

BioNTech AG. Founded in 2008, the company started with a handful of employees, but has grown to employ more than 850 people as Europe’s largest private biotech company working in immunotherapies.

Dr. Ugur Sahin, an accomplished immunologist and experimental cancer researcher, is one of the founders of BioNTech. His research as a professor at the Johannes-Gutenberg University Mainz in the fields of oncology, hematology and immunology, laid the foundation for BioNTech’s success.

Although scientific knowledge and experience are a prerequisite to success, another important aspect is funding: “In order to further pursue research in cancer immunology, to further develop Dr. Sahin’s promising research in the field, and to bring new drug candidates to clinical development, funding was critical,” explains Sean Marett, Chief Business and Commercial Officer at BioNTech.

In January 2018, for instance, the company secured $270 million (€237 million) in a series A financing round. The biotech company will use this capital to work on its clinical pipeline of individualized immunotherapies, which covers novel approaches such as mRNA and CAR-T for the treatment of cancer and other diseases.

And just this August, BioNTech signed a collaboration agreement with Pfizer for the development of prophylactic mRNA-based vaccine candidates against influenza. Together, they will jointly conduct research, and BioNTech is set to receive a total of $425 million (€374 million) in research, R&D and commercial payments in case a product should be brought to market one day.

Marett sees BioNTech’s secret to success in its “broad scientific knowledge base, and a diverse and experienced team, which brings different perspectives together.” Only then, says Marett, can a biotech company become successful.

https://labiotech.eu/sponsored/guide-biotech-startup-successful-company/




Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk






Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.